1. Home
  2. UTF vs WGSWW Comparison

UTF vs WGSWW Comparison

Compare UTF & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTF
  • WGSWW
  • Stock Information
  • Founded
  • UTF 2004
  • WGSWW N/A
  • Country
  • UTF United States
  • WGSWW United States
  • Employees
  • UTF N/A
  • WGSWW 1000
  • Industry
  • UTF Finance Companies
  • WGSWW Retail: Computer Software & Peripheral Equipment
  • Sector
  • UTF Finance
  • WGSWW Technology
  • Exchange
  • UTF Nasdaq
  • WGSWW Nasdaq
  • Market Cap
  • UTF N/A
  • WGSWW N/A
  • IPO Year
  • UTF N/A
  • WGSWW 2020
  • Fundamental
  • Price
  • UTF $25.55
  • WGSWW $0.17
  • Analyst Decision
  • UTF
  • WGSWW
  • Analyst Count
  • UTF 0
  • WGSWW 0
  • Target Price
  • UTF N/A
  • WGSWW N/A
  • AVG Volume (30 Days)
  • UTF 266.0K
  • WGSWW N/A
  • Earning Date
  • UTF 01-01-0001
  • WGSWW N/A
  • Dividend Yield
  • UTF 8.21%
  • WGSWW N/A
  • EPS Growth
  • UTF N/A
  • WGSWW N/A
  • EPS
  • UTF N/A
  • WGSWW N/A
  • Revenue
  • UTF N/A
  • WGSWW N/A
  • Revenue This Year
  • UTF N/A
  • WGSWW N/A
  • Revenue Next Year
  • UTF N/A
  • WGSWW N/A
  • P/E Ratio
  • UTF N/A
  • WGSWW N/A
  • Revenue Growth
  • UTF N/A
  • WGSWW N/A
  • 52 Week Low
  • UTF $18.15
  • WGSWW N/A
  • 52 Week High
  • UTF $24.49
  • WGSWW N/A
  • Technical
  • Relative Strength Index (RSI)
  • UTF 50.54
  • WGSWW N/A
  • Support Level
  • UTF $25.08
  • WGSWW N/A
  • Resistance Level
  • UTF $25.76
  • WGSWW N/A
  • Average True Range (ATR)
  • UTF 0.30
  • WGSWW 0.00
  • MACD
  • UTF -0.07
  • WGSWW 0.00
  • Stochastic Oscillator
  • UTF 37.80
  • WGSWW 0.00

About WGSWW GeneDx Holdings Corp.

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

Share on Social Networks: